Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. is a recognized specialty pharmaceutical company that uses state-of-the-art, cGMP compliant facilities to develop, manufacture, and market injectable and inhalation products. Amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. We currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. Amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the U.S. enables it to establish significant market share upon the introduction of its new products.
Company Growth (employees)
Rancho Cucamonga, US
Size (employees)
1,460 (est)
Amphastar Pharmaceuticals was founded in 1996 and is headquartered in Rancho Cucamonga, US

Amphastar Pharmaceuticals Office Locations

Amphastar Pharmaceuticals has an office in Rancho Cucamonga
Rancho Cucamonga, US (HQ)
11570 6th St

Amphastar Pharmaceuticals Metrics

Amphastar Pharmaceuticals Financial Metrics

Revenue (2016)

$255.2 m

Revenue growth (2015-16), %


Gross profit

$104.2 m

Gross profit margin (2016), %


Net income (2016)

$10.5 m

Market capitalization (28-Apr-2017)

$693.2 m

Closing share price (28-Apr-2017)


Cash (31-Dec-2016)

$72.4 m
Amphastar Pharmaceuticals's current market capitalization is $693.2 m.
Amphastar Pharmaceuticals's revenue was reported to be $255.2 m in FY, 2016 which is a 1% increase from the previous period.
FY, 2014FY, 2015FY, 2016


$210.5 m$251.5 m$255.2 m

Revenue growth, %


Cost of goods sold

$159.2 m$174.2 m$151 m

Gross profit

$51.3 m$77.3 m$104.2 m

Gross profit Margin, %


Sales and marketing expense

$5.6 m$5.5 m$5.5 m

R&D expense

$28.4 m$37.1 m$41.2 m

General and administrative expense

$34.8 m$41.5 m$41.8 m

Operating expense total

$69.2 m$84.2 m$88.5 m


($18 m)($6.9 m)$15.7 m

EBIT margin, %


Interest expense

($609 k)($987 k)($1 m)

Interest income

$243 k$315 k$270 k

Pre tax profit

($18.1 m)($10.4 m)$14.9 m

Income tax expense

($7.4 m)($7.6 m)$4.4 m

Net Income

($10.7 m)($2.8 m)$10.5 m
Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016


$50.2 m$53.6 m$67.8 m$66.1 m$72.4 m

Accounts Receivable

$364.7 m


$118.4 m

Current Assets

$198 m$175.9 m$184.1 m


$138.3 m$142.2 m$152.9 m


$42.6 m$39.9 m$50.3 m

Total Assets

$389.4 m$390.1 m$427.7 m

Accounts Payable

$36.4 m

Current Liabilities

$62.6 m$60 m$60.6 m

Additional Paid-in Capital

$220.7 m$247.8 m$283.1 m

Retained Earnings

$63.1 m$60.3 m$70.9 m

Total Equity

$295.5 m$329.3 m

Financial Leverage

1.3 x1.3 x
FY, 2014FY, 2015FY, 2016

Net Income

($10.7 m)($2.8 m)$10.5 m

Depreciation and Amortization

$12 m

Accounts Receivable

$17.1 m


$9.1 m

Accounts Payable

$7 m

Cash From Operating Activities

$14.2 m($1.8 m)$38.6 m

Purchases of PP&E

($18.7 m)

Cash From Investing Activities

($39.8 m)($39.5 m)

Long-term Borrowings

($8.2 m)($14.7 m)

Cash From Financing Activities

$32.1 m$7.1 m

Interest Paid

$2.6 m

Income Taxes Paid

$436 k$3.4 m

Amphastar Pharmaceuticals Operating Metrics

FY, 2016





Amphastar Pharmaceuticals Market Value History

Amphastar Pharmaceuticals Revenue Breakdown

Amphastar Pharmaceuticals Median Salaries

Source: 12 public H-1B filings from Amphastar Pharmaceuticals

Amphastar Pharmaceuticals News

Amphastar Pharmaceuticals Company Life

You may also be interested in